Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | TLR4 | O00206 | 1/20 | 0.57 |
| ▸ | TLR2 | O60603 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 7/20 | 0.54 |
| ▸ | MAOB | P27338 | 7/20 | 0.54 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.51 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6289516 | 1.00 | TSHR (0.59) | TSHRTLR4TLR2MAOAMAOB | |
| SCHEMBL8796357 | 1.00 | TSHR (0.59) | TSHRTLR4TLR2MAOAMAOB | |
| SCHEMBL10498103 | 1.00 | TSHR (0.59) | TSHRTLR4TLR2MAOAMAOB | |
| SCHEMBL7756955 | 1.00 | TSHR (0.59) | TSHRTLR4TLR2MAOAMAOB | |
| SCHEMBL3904389 | 1.00 | TSHR (0.59) | TSHRTLR4TLR2MAOAMAOB | |
| SCHEMBL10497495 | 1.00 | TSHR (0.59) | TSHRTLR4TLR2MAOAMAOB | |
| SCHEMBL584475 | 1.00 | TSHR (0.59) | TSHRTLR4TLR2MAOAMAOB | |
| SCHEMBL10497968 | 1.00 | TSHR (0.59) | TSHRTLR4TLR2MAOAMAOB | |
| SCHEMBL8863665 | 1.00 | TSHR (0.59) | TSHRTLR4TLR2MAOAMAOB | |
| SCHEMBL10497778 | 1.00 | TSHR (0.59) | TSHRTLR4TLR2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768666-B1 | NOVEL USES OF PORPHYRIN COMPOUNDS | DESTINY PHARMA LTD (GB) | 2012-02-15 | — | — | EP | disclosed |
| US-7977474-B2 | Uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| EP-1897883-A2 | Cationic porphyrin derivatives as antibacterial agents | Destiny Pharma Limited (GB) | 2008-03-12 | — | — | EP | disclosed |
| EP-1578750-B1 | CATIONIC PORPHYRIN DERIVATIVES AS ANTIBACTERIAL AGENTS | DESTINY PHARMA LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| US-20070167619-A1 | Novel uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2007-07-19 | — | — | US | disclosed |
| US-7244841-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| EP-1768666-A1 | NOVEL USES OF PORPHYRIN COMPOUNDS | Destiny Pharma Limited (GB) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006000765-A1 | NOVEL USES | DESTINY PHARMA LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
| EP-1578750-A2 | CATIONIC PORPHYRIN DERIVATIVES AS ANTIBACTERIAL AGENTS | Destiny Pharma Limited (GB) | 2005-09-28 | — | — | EP | disclosed |
| US-20040143001-A1 | Novel compounds and uses thereof | DESTINY PHARMA LIMITED | 2004-07-22 | — | — | US | disclosed |
| WO-2004056828-A2 | NOVEL COMPOUNDS AND USES THEREOF | DESTINY PHARMA LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167619-A1 | Novel uses of porphyrin compounds | PPOX, ZFX, ZYX | TSHR 3362/4885TLR4 234/4885TLR2 788/4885 |
| US-20040143001-A1 | Novel compounds and uses thereof | PPOX, CYP19A1, XDH | TSHR 3602/4885TLR4 540/4885TLR2 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.